1024602-82-1Relevant articles and documents
NOVEL CONJUGATION CHEMISTRY FOR CATALYTIC ANTTIBODY 38C2
-
Paragraph 0092; 00105, (2021/04/30)
The present invention provides modified catalytic antibody 38C2 with arylation of the reactive lysine residue (Lys99). The Lys99 residue is arylated with a heteroaryl methyl sulfonyl compound such as methylsulfone phenyl oxadi azole (MS- PODA). The invention also provides antibody conjugated agents (e.g., antibody drug conjugates) that contain an agent moiety that is site-specifically conjugated to 38C2 via a methyl sulfonyl compound. Further provided in the invention are methods of making the antibody conjugated agents and therapeutic applications of the antibody conjugated agents.
Chromatography- and lyophilization-free synthesis of a peptide- linker conjugate
Magano, Javier,Bock, Brandon,Brennan, John,Farrand, Douglas,Lovdahl, Michael,Maloney, Mark T.,Nadkarni, Durgesh,Oliver, Wendy K.,Pozzo, Mark J.,Teixeira, John J.,Wang, Jian,Rizzo, John,Tumelty, David
, p. 142 - 151 (2014/05/20)
An optimized and scalable process to manufacture peptide-linker conjugate 1 is reported that avoids the chromatographic purification and lyophilization that are typically required for the isolation of this type of compound. An operationally simple protoco
Development of novel linkers to conjugate pharmacophores to a carrier antibody
Palanki, Moorthy S.S.,Bhat, Abhijit,Lappe, Rodney W.,Liu, Bin,Oates, Bryan,Rizzo, John,Stankovic, Nebojsa,Bradshaw, Curt
, p. 4249 - 4253 (2012/07/17)
We have developed modified maleimide novel linkers with improved chemical stability that could potentially be used in conjugating various pharmacophores such as oligo nucleotides, peptides, and proteins to antibodies to afford novel biologics with well-de
